Profile of Silodosin. Francesco Montorsi * Article info. Abstract
|
|
- Dorothy Walsh
- 5 years ago
- Views:
Transcription
1 EUROPEAN UROLOGY SUPPLEMENTS 9 (2010) available at journal homepage: Profile of Silodosin Francesco Montorsi * Department of Urology, University Vita-Salute San Raffaele, Scientific Institute H. San Raffaele, Milan, Italy Article info Keywords: a1a-adrenoceptor antagonist Silodosin Tamsulosin Pharmacology Efficacy Safety Abstract Silodosin is a highly selective a1a-adrenoceptor antagonist approved for the treatment of the signs and symptoms of benign prostatic hyperplasia. Its clinical pharmacology profile offers a number of advantages, including uroselectivity, once-daily (QD) dosing, a standard dose of 8 mg QD that does not need to be adjusted according to age, and the feasibility of concomitant treatment with phosphodiesterase type 5 (PDE5) inhibitors and antihypertensive agents. Three phase 3 double-blind, randomised trials using the dosage regimen of 8 mg QD in >800 patients have shown that silodosin is significantly more effective than placebo ( p < 0.001) and at least as effective as tamsulosin (0.4 mg QD) in improving International Prostate Symptom Score (IPSS) total score, storage subscore, and voiding subscore. It is significantly more effective than tamsulosin in inducing simultaneous improvement of bothersome lower urinary tract symptoms such as incomplete emptying, frequency, and nocturia ( p = 0.03). Safety data collected in 1581 patients exposed to chronic treatment with silodosin 8 mg QD have shown that the drug is safe and well tolerated. As was to be expected with a uroselective compound, cardiovascular effects have been minimal. The most common adverse reaction is retrograde ejaculation (anejaculation), which led to treatment discontinuation in only 3.9% of patients. The rare, drug class related safety issue of intraocular floppy iris syndrome can be satisfactorily managed by warning patients simply to inform their ophthalmologist that they are or were on treatment with an a1-adrenoceptor blocker. # 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved. * Tel.: ; fax: address: montorsi.francesco@hsr.it. 1. Introduction Silodosin is an a1-adrenoceptor antagonist with unequalled selectivity for the a1a-adrenoceptor subtype (a1a-to-a1b binding ratio: 162:1) (unpubl data, Recordati [1]). Silodosin is approved for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in Europe, the United States, and Japan. As with many other medicinal products, the recommended dose is different in Europe and the United States as compared to Japan: one 8-mg capsule daily (with a starting dose of one 4-mg capsule daily in patients with moderate renal function impairment) in both Europe and the United States versus either one 2-mg or 4-mg capsule twice daily in Japan. 2. Clinical pharmacology 2.1. The importance of a1a-adrenoceptor selectivity The function of the three a1-adrenoceptor subtypes differs considerably: The a1a receptors predominate in mediating prostate contraction and the human urethra contains only a1a receptors [2,3], whereas a1a, a1b, and a1d all mediate blood vessel dilation [4]. Consequently, the high selectivity /$ see front matter # 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved. doi: /j.eursup
2 492 EUROPEAN UROLOGY SUPPLEMENTS 9 (2010) of silodosin for the a1a subtype should result in better cardiovascular tolerability without any loss of efficacy on urinary tract symptoms, as compared to less selective a-adrenoceptor blockers. Indeed, negligible effects on the cardiovascular system have been documented in the animal model as well as in studies in healthy volunteers. Moderate effects on blood pressure and no effects on cardiac repolarisation were recorded in dogs given oral doses of silodosin up to 200 times the standard therapeutic dose proposed for humans [5]. No meaningful effects on heart rate, pulse rate, and QRS interval duration were observed in healthy volunteers receiving silodosin at a dose three times higher than that proposed as the standard therapeutic dose (24 mg) [6] Pharmacokinetics The pharmacokinetic profile of silodosin enables once-daily (QD) dosing and a standard dosage regimen that does not have to be tailored to the patient, with the only exception being patients with moderate impairment of renal function. Silodosin is readily absorbed from the gut, and peak plasma concentration (C max ) and area under the curve (AUC) for plasma concentration versus time increase linearly with dose [7]. Absolute bioavailability amounts to approximately 32% [8]. Food blunts C max and delays time to C max by about 1 h without affecting the AUC. This feature has been exploited by recommending the administration of silodosin with food, ideally during breakfast in the morning, to avoid plasma concentration peaks that could potentially be associated with adverse effects [7 9]. Silodosin undergoes extensive metabolism through glucuronidation, alcohol and aldehyde dehydrogenase, and oxidative pathways involving CYP3A4. The main metabolite in plasma is the glucuronide conjugate, which is active and reaches concentrations that are three to four times higher than those of the parent compound. Both silodosin and its glucuronide conjugate have a long terminal half-life that makes QD dosing feasible (approximately 11 and 18 h, respectively) [8 10]. Studies in special populations of patients have established that the pharmacokinetic profile of silodosin does not change significantly with age and that body clearance does not diminish, even with advanced age (>85 yr) [11]. Thus, the standard dose of one 8-mg capsule daily can be administered even to elderly patients a very important factor, as the prevalence of BPH increases steeply with age. Dosage adjustment is also not an issue for patients with mild renal function impairment or with mild to moderate liver function impairment. A starting dose is required in patients with moderate renal function impairment (one 4- mg capsule daily), with uptitration after 1 wk. Administration of silodosin is not recommended in patients with severe renal or liver function impairment [8] Pharmacologic interactions Silodosin can be prescribed together with other drugs that are commonly used by patients with symptomatic BPH for example, phosphodiesterase type 5 inhibitors (PDE5-I) and antihypertensive agents provided that the patients are monitored for adverse events [8]. In a placebo-controlled, open-label crossover study in 22 healthy subjects aged yr given 8 mg silodosin for 21 d, orthostatic tests showed minimal reductions in systolic and/or diastolic blood pressure after coadministration of silodosin with a PDE5-I (sildenafil 100 mg or tadalafil 20 mg) [12]. Very few of the 500 hypertensive patients included in the phase 3 clinical trial program reported episodes of orthostatic hypotension (n = 7; 1.4%). They were taking a broad range of antihypertensive agents, including drugs acting on the renin angiotensin system (24%), beta blockers (13%), calcium antagonists (8.7%), and diuretics (7.5%). The rate of orthostatic hypotension was similar amongst the 1081 patients included in the clinical trial program who were not on antihypertensive treatment (n = 13; 1.2%). The use of silodosin is not recommended in patients who are on treatment with strong inhibitors of CYP3A4, such as ketoconazole and anti-hiv protease compounds because its metabolism involves this pathway [8]. This precaution does not extend to moderate CYP3A4 inhibitors, such as diltiazem, which has proved not to interact significantly with silodosin (unpubl data, Recordati [1]). 3. Efficacy After a placebo-controlled, dose-finding, 6-wk treatment study in which the improvement in the American Urological Association (AUA) symptom score versus baseline was clearly better with 8 mg QD ( ; n = 90) than with both 4 mg QD ( ; n = 88) or placebo ( ; n = 86) (unpubl data, Recordati [1]), three large double-blind, randomised, pivotal phase 3 clinical trials were carried out with the selected dose regimen (8 mg QD) in >800 patients [8]. Two were placebo-controlled, double-blind trials in the United States designed to demonstrate superiority over placebo and one was a placebo-controlled, double-blind, three-armed clinical trial in Europe designed to demonstrate superiority over placebo and noninferiority to an active comparator (tamsulosin 0.4 mg QD). Patients were randomised to placebo or active treatment for 12 wk after a 4-wk placebo run-in. The randomisation ratio was 1:1 in the US studies and 2:2:1 (1 being the placebo arm) in the European study. The main inclusion criteria for patient recruitment were the same in the three trials and consisted of International Prostate Symptom Score (IPSS) or AUA total symptom score 13 and a maximum urine flow rate (Q max ) of 4 15 ml/s with a minimum voided volume 125 ml. The three clinical trials also had the same primary end point: change in IPSS total score versus baseline. IPSS subscores related to storage and voiding symptoms were taken as secondary end points in addition to the responder rate (only in the European study, defined as the rate of patients who experienced a decrease in IPSS total score 25% compared with baseline) and the Q max. Silodosin was consistently superior to placebo in terms of change in IPSS total score versus baseline in all the three trials (all p < 0.001). The mean difference in IPSS total score
3 EUROPEAN UROLOGY SUPPLEMENTS 9 (2010) Table 1 Total International Prostate Symptom Score (IPSS): superior efficacy versus placebo in two pivotal phase 3 clinical trials Study Treatment arm No. patients IPSS total score Baseline value Change from baseline p value SI04009 Silodosin 8 mg QD <0.001 Placebo SI04010 Silodosin 8 mg QD <0.001 Placebo QD = once daily. versus placebo was always clinically significant, ranging from 2.3 to 2.9 [8] (Table 1). The results were similar when the storage and voiding subscores were taken into consideration, with a trend towards greater efficacy on voiding symptoms. The improvement versus placebo in storage symptom score amounted to 0.9 (95% confidence interval [CI]; 1.4, 0.4) and 1.0 (95% CI; 1.5, 0.6) in the two US trials (both p < 0.001) [13] and to 0.7 (95% CI; 1.1, 0.2) in the European trial ( p = 0.002) [14]; the improvement versus placebo in the voiding symptom score was 1.9 (95% CI; 2.6, 1.2) and 1.8 (95% CI; 2.5, 1.1) in the two US trials and 1.7 (95% CI; 2.2, 1.1) in the European trial (all p < 0.001). The responder rate was also consistently higher with silodosin than with placebo: 52.8% and 53.6% of patients responded to silodosin versus 31.6% and 32.8% to placebo, respectively, in the two US studies (both differences p < ). In the European trial, the responder rate was 68% in the silodosin group and 53% in the placebo group ( p < 0.001) [14]. In the European trial, silodosin was also superior, albeit not significantly so, as compared with tamsulosin in reducing the total IPSS score as well as the storage subscore ( 0.7 vs 0.6) and voiding subscore ( 1.7 vs 1.4) [14]. Itshouldbe borne in mind that the study was designed to demonstrate noninferiority to tamsulosin and superiority over placebo; in the absence of preliminary direct comparisons, the superiority over tamsulosin was not the objective of the study. The same was true for the responder rates: 68% in the silodosin group and 65% in the tamsulosin group, both significantly higher than 53% in the placebo group ( p < for silodosin and p = for tamsulosin) [14]. Nevertheless, all the data were consistently numerically higher with silodosin than with tamsulosin. The measurement of Q max after the first dose in the US studies showed an onset of action within 2 6 h after administration, and the measurement of IPSS during the first week after the introduction of treatment showed that the change in total IPSS versus baseline became clinically meaningful after 3 4 days [13]. A total of 661 patients in the United States and 500 patients in Europe entered an openlabel, long-term phase for up to 12 months. Patients who had previously received placebo experienced larger decreases in total score ( ) than patients who had previously received silodosin, who continued to experience the same degree of improvement in the long term ( ) [15]. Explorative post hoc analyses were carried out to assess the efficacy of silodosin according to the severity of symptoms ( moderate or severe defined as IPSS total score < 20 or 20, respectively) and on nocturia (in view of the potential complications caused by this symptom, such as falls). In addition, the percentage of patients showing a contemporary improvement in three bothersome symptoms (ie, incomplete emptying, frequency, and nocturia) has been evaluated. In fact, these symptoms could be seen as linked. The sensation of incomplete emptying indicates that a lower percent of urinary volume is voided; consequently, the patient is obliged to void more often to empty his bladder during the day (frequency) and during the night (nocturia). The results did not differ according to severity of symptoms. Silodosin was significantly more effective than placebo in reducing both moderate and severe symptoms as compared to placebo in all the three studies ( p < 0.001). Also tamsulosin was significantly more effective than placebo ( p < 0.01), and a slight superiority of silodosin over tamsulosin was recorded in both subgroups (mean difference in total IPSS score change vs placebo: moderate symptoms, 0.4; severe symptoms, 0.3). In the pooled dataset of the three studies, the mean number of nocturia episodes diminished significantly by 0.2 episodes per night (95% CI; 0.3, 0.1; p < 0.001); also the percentage of patients reporting an improvement was significantly higher in the silodosin group (53.4% vs 42.8%; p < 0.001). The findings were similar in the subgroup of patients who reported 2 episodes at baseline: The mean difference in score between treatments was 0.2 (95% CI; 0.3, 0.1; p < 0.001), and the improvement rate was 60.6% in the silodosin group versus 48.7% in the placebo group ( p < ). In the European study, the percentage of the intention-to-treat (ITT) population that reported a reduction in mean nocturia versus baseline by at least one episode was significantly higher in the silodosin group than in the placebo group (59% vs 45%; p = 0.01), whereas the difference between the tamsulosin group and the placebo group was not significant (54% vs 45%). The same was true in the subgroup of patients who reported at least two episodes of nocturia at baseline (silodosin 67%, tamsulosin 63%, placebo 55%; p < 0.05 only silodosin vs placebo; Fig. 1). In the pooled dataset, the percentage of patients with simultaneous improvement in the three bothersome symptoms (incomplete emptying, frequency, and nocturia) was significantly higher in the silodosin group than in the placebo group, both in the ITT population (30.5% vs 20.2%; p < ) and in the subgroup of patients who reported two or more episodes of nocturia at baseline (34.9% vs 23.2%; p < ). In the European study, the improvement
4 494 EUROPEAN UROLOGY SUPPLEMENTS 9 (2010) Fig. 1 Percentage of patients with reduction of at least one episode of nocturia (placebo = 148; silodosin = 308; tamsulosin = 308). * p < 0.05 versus placebo. Fig. 2 Percentage of patients with simultaneous improvement in incomplete emptying, frequency, and nocturia (patient population and subgroup with two or more episodes of nocturia). p = 0.02 versus placebo; p = 0.03 versus tamsulosin. # p = 0.04 versus placebo; p = 0.03 versus tamsulosin. in the percentage of these patients was significantly higher with silodosin than with both tamsulosin ( p = 0.03) and placebo ( p = 0.02; Fig. 2) (unpubl data, Recordati [1]). 4. Safety A total of 1581 patients were exposed to chronic treatment with silodosin 8 mg QD. Of these, 961 patients (62.4%) were exposed for 6 months and 384 patients (24.9%) for 12 months [8]. In the placebo-controlled studies, 28.8% of patients given silodosin (n = 931) experienced one drugrelated adverse event or more compared with 9% of patients in the placebo group (n = 733). Out of the 1581 patients exposed to silodosin, 31.8% reported one drug-related adverse event or more (Table 2). In the placebo-controlled trials, 4.3% of patients discontinued treatment because of an adverse event in the silodosin groups versus 1.9% in the placebo groups; thus, the difference between active treatment and placebo amounted to only 2.4%. The main adverse events that caused discontinuation were retrograde ejaculation (3.9%), dizziness (0.5%), and orthostatic hypotension in 0.2% of patients. The most common adverse reactions reported were the same reactions that caused the discontinuations: retrograde ejaculation (21.5% of patients in placebo-controlled trials vs 0.8% with placebo; 23.6% overall), followed by dizziness (1.8% in placebo-controlled trials vs 0.8% with placebo; 2.1% overall). Other adverse reactions reported by 1% of patients overall were orthostatic hypotension, nasal congestion, and headache (all 1.3%) as well as diarrhoea (1.0%). It is interesting to note that, considering the US and European studies overall, 32% of patients concomitantly took antihypertensive medications. Nevertheless, no statistically significant differences in orthostatic hypotension have been shown versus placebo (1.4% vs 1% respectively). Retrograde ejaculation does not appear to be particularly bothersome. Whereas >20% of patients reported this adverse effect, only 3.9% discontinued treatment because of it. Furthermore, this effect is fully and promptly reversible within a few days after discontinuation of treatment [8]. The most likely explanation for the difference between the occurrence rate and discontinuation rate is that patients with lower urinary tract symptoms (LUTS) often suffer from initial sexual dysfunction, including diminished ejaculation, independent of any subsequent treatment [16]. This effect was historically called retrograde ejaculation, because it was believed that failure to ejaculate was the result of smooth muscle relaxation in the prostate, urethra, and bladder neck leading to abnormal urethral flow, as is the case after transurethral resection of the prostate. However, recent studies have shown that the mechanism is rather a loss of seminal emission resulting Table 2 Safety profile of silodosin in placebo-controlled trials * Preferred term Placebo-controlled studies All studies Silodosin 8 mg (n = 931) Placebo (n = 733) Silodosin (n = 1581) Patients with drug-related adverse events, n (%) 268 (28.8) 66 (9.0) 502 (31.8) Retrograde ejaculation, n (%) 200 (21.5) 6 (0.8) 373 (23.6) Dizziness, n (%) 17 (1.8) 6 (0.8) 33 (2.1) Orthostatic hypotension, n (%) 11 (1.2) 7 (1.0) 20 (1.3) Nasal congestion, n (%) 9 (1.0) 1 (0.1) 20 (1.3) Headache, n (%) 10 (1.1) 9 (1.2) 20 (1.3) Diarrhoea, n (%) 6 (0.6) 2 (0.3) 16 (1.0) * Source: Silodosin Integrated Summary of Safety (September 2008).
5 EUROPEAN UROLOGY SUPPLEMENTS 9 (2010) from relaxation of the vas deferens [17,18]. Thus, the correct term for the observed effect is anejaculation. An unresolved issue is whether anejaculation has an impact on the quality of orgasm. According to a preliminary randomised, double-blind crossover study in 15 healthy volunteers, orgasm is preserved regardless of ejaculatory dysfunction [19]. Isolated reports of intraoperative floppy iris syndrome (IFIS) manifesting with the triad of pupil constriction, fluttering, and billowing of the iris stroma together with the tendency of the iris to prolapse during cataract surgery have been received with a1 blockers, mainly tamsulosin. However, reports have also been received with other a1 blockers. The event is believed to be a drug class effect resulting from inhibition of the iris dilator muscle [20]. A few cases of IFIS occurred with silodosin in Japan, and one case occurred with silodosin in the US open-label study before investigators were warned about the risk of this event. No cases have been reported in Europe after patients were warned about the risk. 5. Conclusions Silodosin is a novel a1-adrenoceptor blocker that is highly selective for the a1a receptor subset responsible for prostatic and urethral contractility. At the dosage regimen of 8 mg QD, it has proved to be significantly more effective than placebo in controlling LUTS and at least as effective as tamsulosin. Moreover, it is significantly more effective than tamsulosin in inducing simultaneous improvement of some of the most bothersome LUTS (ie, incomplete emptying, frequency, and nocturia). Extensive long-term exposure for up to 1 yr has shown that silodosin is safe and well tolerated. As was to be expected with a highly uroselective compound, the cardiovascular effects of silodosin are minimal. The most common adverse reaction is anejaculation, which was not bothersome in most patients. The rare, drug class related safety issue of IFIS can be satisfactorily managed by warning patients simply to inform their ophthalmologist that they are or were on treatment with an a1-adrenoceptor blocker. Conflicts of interest In recent years, the author has received research support, consultancy, and/or lecturer honoraria in the field of a1- adrenoceptors from Recordati. References [1] Unpubl. data, Recordati SpA, Milano, Italy. Summary of Safety (September 2008), Common Technical Documents on file, Recordati, Milano, Italy. [2] Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006;147: S [3] Roehrborn CG. Efficacy of a-adrenergic receptor blockers in the treatment of male lower urinary tract symptoms. Rev Urol 2009; 11(Suppl 1):S1 8. [4] Guimaraes S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev 2001;53: [5] Tatemichi S, Kiguchi S, Kobayashi M, Yamazaki Y, Shibata N, Uruno T. Cardiovascular effects of the selective alpha1a-adrenoceptor antagonist silodosin (KMD-3213), a drug for the treatment of voiding dysfunction. Arzneimittelforschung 2006;56: [6] Morganroth J, Lepor H, Hill LA, Volinn W, Hoel G. Effects of the selective alpha(1a)-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double-blind, placebo- and moxifloxacin-controlled study. Clin Pharmacol Ther 2010;87: [7] Yoshida M, Homma Y, Kawabe K, Silodosin. a novel selective a1a adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia. Exp Opin Invest Drugs 2007;16: [8] EPARs for authorised medicinal products for human use: Urorec. European Medicines Agency Web site. humandocs/humans/epar/urorec/urorec.htm. [9] Guay DRP. Silodosin: an orally active selective a1-adrenoceptor antagonist for benign prostatic hyperplasia. Aging Health 2009; 5: [10] Matsubara Y, Kanazawa T, Kojima Y, et al. Pharmacokinetics and disposition of silodosin (KMD-3213). Yakugaku Zasshi 2006;126: [11] Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997;158: [12] Macdiarmid SA, Hill LA, Volinn W, Hoel G. Lack of pharmacodynamic interaction of silodosin, a highly selective alpha1a-adrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men. Urology 2010;75: [13] Marks L, Gittelmann MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha 1A-adrenoceptor antagonists silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009;181: [14] Chapple C. Eur Urol. In press. [15] Marks L, Gittelmann MC, Hill LA, Volinn W, Hoel G. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Urology 2009;74: [16] Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol 2003;44: [17] Michel MC. a1-adrenoceptors and ejaculatory function. Br J Pharmacol 2007;152: [18] Kobayashi K, Masumori N, Hisasue S, et al. Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective a1a-blocker in normal volunteers. J Sex Med 2008;5: [19] Kobayashi K, Masumori N, Kato R, et al. Orgasm is preserved regardless of ejaculatory dysfunction with selective alpha1a-blocker administration. Int J Impot Res 2009;21: [20] Avisar R, Weinberger D. Intraoperative floppy iris syndrome: possible relationship with alpha-1 adrenergic receptor antagonists. IMAJ 2009;11:42 4.
SILOFAST Capsules (Silodosin)
Published on: 10 Jul 2014 SILOFAST Capsules (Silodosin) Composition SILOFAST-4 Capsules Each hard gelatin capsule contains: Silodosin 4 mg Approved colours used in capsule shell SILOFAST-8 Capsules Each
More informationEjaculation. Emission. Ejection. Orgasm
Ejaculation Emission Ejection Orgasm Ejaculation sc T10-L2 S2-4 Emission: vas deferens, prostate, bladder neck Post. Urethra distention Ejection: Pelvic Floor / bulbocavernous muscle contraction Orgasm:
More informationThe Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (6), Page
The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (6), Page 1377-1386 Evaluation of Silodosin in Comparison to Tamuslosin in Treatment of Benign Prostatic Hyperplasia with lower Urinary
More informationThe Pharmacological Profile of the a 1A -Adrenoceptor Antagonist Silodosin
EUROPEAN UROLOGY SUPPLEMENTS 9 (2010) 486 490 available at www.sciencedirect.com journal homepage: www.europeanurology.com The Pharmacological Profile of the a 1A -Adrenoceptor Antagonist Silodosin Martin
More informationSilodosin versus naftopidil for the treatment of benign prostatic hyperplasia: A multicenter randomized trial
The study protocol was approved by the ethics committee and institutional review board of Nihon University School of Medicine. Written informed consent was obtained from all patients. From December 2007
More informationAlpha antagonists from initial concept to routine clinical practice
european urology 50 (2006) 635 642 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Alpha antagonists from initial concept to routine clinical practice
More informationALFUSIN Tablets (Alfuzosin hydrochloride)
Published on: 20 Sep 2014 ALFUSIN Tablets (Alfuzosin hydrochloride) Composition Each film-coated extended-release tablet contains: Alfuzosin hydrochloride Ph.Eur... 10 mg Dosage Form Extended-release tablet
More informationURIMAX Capsules (Tamsulosin hydrochloride)
Published on: 22 Sep 2014 URIMAX Capsules (Tamsulosin hydrochloride) Composition URIMAX-0.2 Capsules Each capsule contains: Tamsulosin Hydrochloride... 200 mcg (as modified-release pellets) URIMAX-0.4
More informationInvestigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia
Sakata and Morita BMC Urology 2012, 12:29 RESEARCH ARTICLE Open Access Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia Koichi Sakata 1* and Tatsuo Morita 2
More informationOriginal Article INTRODUCTION. Abstract
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2017/02 Comparison of Silodosin with Tamsulosin in Patients with Symptomatic Benign Prostatic Hyperplasia: A Prospective,
More informationMMM. Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS
Dr Tan & Partners MMM Vol. 1 No. 1 Morbidity & Mortality Meeting 14 th November 2014 Introduction Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS Tadalafil 5mg daily is a well established
More informationOriginal Article - Voiding Dysfunction
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.5.335 Original Article - Voiding Dysfunction http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.5.335&domain=pdf&date_stamp=2014-05-16
More informationSilodosin From Bench to Bedside: Selectivity, Safety, and Sustained Efficacy
EUROPEAN UROLOGY SUPPLEMENTS 10 (2011) 445 450 available at www.sciencedirect.com journal homepage: www.europeanurology.com Silodosin From Bench to Bedside: Selectivity, Safety, and Sustained Efficacy
More informationNew Treatment Modalities for Benign Prostatic Hyperplasia. Seung-June Oh, MD Department of Urology, Seoul National University Hospital
New Treatment Modalities for Benign Prostatic Hyperplasia Seung-June Oh, MD Department of Urology, Seoul National University Hospital Options for Treating BPH Pharmacotherapy blocker Agents for BPH + OAB
More informationMedical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily
REVIEW Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily Claus G Roehrborn 1 Raymond C Rosen 2 1 Department of Urology, University of Texas Southwestern
More informationLONG-TERM SAFETY AND EFFICACY OF TAMSULOSIN FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA
0022-5347/03/1702-0498/0 Vol. 170, 498 502, August 2003 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000076140.68657.fd LONG-TERM SAFETY
More informationNational Institute for Health and Care Excellence. Lower Urinary Tract Symptoms Update Addendum Consultation Table 3 rd February 5 pm 3 rd March 2015
British Association of Urological Surgeons British Association of Urological Surgeons National Institute for Health and Care Excellence Lower Urinary Tract Symptoms Update Addendum Consultation Table 3
More informationPage 1 of 19. SILODOSIN capsules, for oral use Initial U.S. Approval: 2008
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SILODOSIN CAPSULES safely and effectively. See full prescribing information for SILODOSIN CAPSULES.
More informationBenign Prostatic Hyperplasia. Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary
Benign Prostatic Hyperplasia Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied,
More informationEfficacy and safety of tamsulosin OCAS
Original Article EFFICACY AND SAFETY OF TAMSULOSIN OCAS SPEAKMAN Efficacy and safety of tamsulosin OCAS MARK SPEAKMAN Taunton and Somerset Hospital, Taunton, UK The efficacy and safety of a new tablet
More informationMEDICAL THERAPY. Endocrine Approaches. Página 1 de 5.
Página 1 de 5 MEDICAL THERAPY Part of "32 - BENIGN PROSTATIC HYPERPLASIA" Use of pharmacologically defined and a variety of so-called alternative medications to attempt to improve BPH voiding dysfunction
More informationEVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT
Basrah Journal Of Surgery EVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT MB, ChB, FIBMS, Assistant Professor
More informationIncreasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP
Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of
More informationBenign Prostatic Hyperplasia (BPH) IPT VI Srikanth Kolluru, Ph.D
Benign Prostatic yperplasia (BP) IPT VI Srikanth Kolluru, Ph.D. kolluru@tamhsc.edu, 361 221 0741 verview 1. Introduction and background of BP 2. Causes and common symptoms 3. Treatment options Learning
More informationHarnalidge OCAS Prolonged Release Tablets 0.4 mg
Harnalidge OCAS Prolonged Release Tablets 0.4 mg License number: 025413 Physician use only Each prolonged release film-coated tablet contains 0.4 mg tamsulosin
More informationBenign Prostatic Hyperplasia (BPH):
Benign Prostatic Hyperplasia (BPH): Evidence Based Guidelines for Primary Care Providers Jeanne Martin, DNP, ANP-BC Objectives 1. Understand the pathophysiology and prevalence of BPH 2. Select the appropriate
More informationPRODUCT MONOGRAPH RAPAFLO. Silodosin. Capsules, 8 mg and 4 mg. ATC code: G04C A04
PRODUCT MONOGRAPH Pr RAPAFLO Silodosin Capsules, 8 mg and 4 mg Selective antagonist for ALPHA1A Adrenoreceptor subtype in the prostate and bladder ATC code: G04C A04 Allergan Pharma Co. 500 85 Enterprise
More informationPackage Leaflet: Information for the patient. Urorec 8 mg hard capsules Urorec 4 mg hard capsules Silodosin
Package Leaflet: Information for the patient Urorec 8 mg hard capsules Urorec 4 mg hard capsules Silodosin Read all of this leaflet carefully before you start using this medicine because it contains important
More informationThe Evolution of Combination Therapy. US men eligible for BPH treatment * with projected population changes
The Management of BPH & The Impact of Combination Therapy Results Combination of Avodart and Tamsulosin (CombAT) Medical Therapy of Prostate Symptoms (MTOPS) Dr. Jack Barkin, md, fics, facs, dabu, Mcert
More informationBenign Prostatic Hyperplasia. Management of Benign Prostatic Hyperplasia. Goals of Therapy
Benign Prostatic Hyperplasia Management of Benign Prostatic Hyperplasia Goals of Therapy Improve or abolish lower urinary tract symptoms (LUTS) Prevent or delay clinical progression of benign prostatic
More informationTable of Contents. Page 1 of 20
Table of Contents Highlights of Prescribing Information 3 Indications and Usage 3 Dosage and Administration 3 Dosage forms and Strengths 3 Contraindications 3 Warnings and Precautions 3 Adverse Reactions
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablative therapies, transurethral needle ablation, Adverse events, sexual side effects of BPH Aging, and incidence of BPH associated with
More informationCorrespondence should be addressed to Yoshinori Tanaka;
Hindawi Advances in Urology Volume 2017, Article ID 4842025, 6 pages https://doi.org/10.1155/2017/4842025 Clinical Study The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment
More informationVoiding Dysfunction. Hyo Serk Lee, Sae Woong Kim 1, Seung-June Oh 2, Myung-Soo Choo 3, Kyu-Sung Lee
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.3.178 Voiding Dysfunction Efficacy and Safety of Tamsulosin for Treating Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia:
More information50% of men. 90% of men PATIENT FACTSHEET: BPH CONDITION AND TREATMENTS. Want more information? What are the symptoms?
PATIENT FACTSHEET: BPH CONDITION AND TREATMENTS What is Benign Prostatic Hyperplasia (enlarged prostate)? Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate, the gland that
More informationKey words: Lower Urinary Tract Symptoms (LUTS), Prostatic Hyperplasia, Alpha-1 Adrenoceptor Antagonists, Tamsulosin, Terazosin.
The Professional Medical Journal DOI: 10.17957/TPMJ/17.4102 ORIGINAL PROF-4102 PROSTATIC HYPERPLASIA; COMPARISON BETWEEN TAMSULOSIN AND TERAZOSIN FOR EFFICACY IN MEDICAL MANAGEMENT OF LOWER URINARY TRACT
More informationSUMMARY OF THE PRODUCT CHARACTERISTICS
SUMMARY OF THE PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Xatral OD 10 mg prolonged-release tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each prolonged-release tablet contains Alfuzosin
More informationNOTE: This policy is not effective until April 1, Transurethral Water Vapor Thermal Therapy of the Prostate
NOTE: This policy is not effective until April 1, 2019. Medical Policy Manual Surgery, Policy No. 210 Transurethral Water Vapor Thermal Therapy of the Prostate Next Review: December 2019 Last Review: December
More informationEvaluation of Sexual Dysfunction in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Patients
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2018/10 Evaluation of Sexual Dysfunction in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Patients N. Narayanamoorthy,
More informationDIAGNOSED WITH BENIGN PROSTATIC HYPERPLASIA
Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 74 No. 4 pp. 1247ñ1253, 2017 ISSN 0001-6837 Polish Pharmaceutical Society PHARMACOLOGY CLINICAL EVALUATION OF α-1-adrenolytics IN PATIENTS DIAGNOSED WITH
More informationCOMPOSITION. A film coated tablet contains. Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar (Film coated tablets) Irbesartan
Rotazar (Film coated tablets) Irbesartan Rotazar 75 mg, 150 mg, 300 mg COMPOSITION A film coated tablet contains Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar 75 mg, 150 mg, 300 mg PHARMACOLOGICAL
More informationDuring the past decade, numerous
Benign prostatic hyperplasia (BPH) is one of the most common diseases of aging men. It is estimated that by age 60 years, greater than 50% of men will have histologically documented evidence of the disease.
More informationOmnic 0,4, 0.4 mg, modified release capsules, hard 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Omnic 0,4 (Tamsulosin hydrochloride) Astellas CTD Module 1.3.1 1. NAME OF THE MEDICINAL PRODUCT Omnic 0,4, 0.4 mg, modified release capsules, hard 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Alfuzosin HCl Ranbaxy 10 mg tablets, prolonged-release tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg
More informationThe Journal of International Medical Research 2012; 40:
The Journal of International Medical Research 2012; 40: 899 908 Comparison of α-blocker Monotherapy and α-blocker Plus 5α-Reductase Inhibitor Combination Therapy Based on Prostate Volume for Treatment
More informationJMSCR Vol 05 Issue 07 Page July 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i7.47 Original Research Article Tadalafil therapy
More informationTherapeutic Strategies for Managing BPH Progression
european urology supplements 5 (2006) 997 1003 available at www.sciencedirect.com journal homepage: www.europeanurology.com Therapeutic Strategies for Managing BPH Progression John M. Fitzpatrick a, *,
More informationH6D-MC-LVHR Clinical Study Report Synopsis Page LVHR Synopsis (LY450190)
H6D-MC-LVHR Clinical Study Report Synopsis Page 1 2. LVHR Synopsis H6D-MC-LVHR Clinical Study Report Synopsis Page 2 Clinical Study Report Synopsis: Study H6D-MC-LVHR Title of Study: A Randomized, Double-Blind,
More informationAlfuzosin Hydrochloride Extended-release Tablets USP, for oral use Initial U.S. Approval: 2003
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use alfuzosin hydrochloride extended-release tablets safely and effectively. See full prescribing information
More informationSystematic Review of Combination Drug Therapy for Non-neurogenic Male Lower Urinary Tract Symptoms
EUROPEAN UROLOGY 64 (2013) 228 243 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Collaborative Review Benign Prostatic Hyperplasia Editorial by Herbert
More informationOriginal Article Japanese Urological Association. International Journal of Urology (2006) 13,
Blackwell Publishing AsiaMelbourne, AustraliaIJUInternational Journal of Urology0919-81722006 Blackwell Publishing Asia Pty Ltd2006130014051409Original ArticleTamsulosin vs doxazosin in BPH D Rahardjo
More informationOriginal Article. Introduction. Methods. Abstract
Blackwell Science, LtdOxford, UKIJUInternational Journal of Urology0919-81722003 Blackwell Publishing Asia Pty LtdNovember 20031011587594Original ArticleUsefulness of a1-blockers in BPHI Ikemoto et al.
More informationTreating BPH: Comparing Rezum UroLift and HoLEP
Treating BPH: Comparing Rezum UroLift and HoLEP Scott M. Cheney MD Mayo Clinic Arizona 2018 MFMER slide-1 Welcome to AZ 2018 MFMER slide-2 Outline Background on BPH, Rezum, Urolift, HoLEP AUA Guideline
More informationLiterature Scan: Drugs for BPH
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationBPH: a present and future perspective on health impact
BPH: a present and future perspective on health impact Burden of disease in men with moderate LUTS Dalibor Pacík This presentation is financially supported by GlaxoSmithKline. CZ/DUTT/0019/12 Men with
More informationInternational Clinical Development Department, Yamanouchi Pharmaceutical Co., Ltd., 17 1 Hasune 3-chome, Itabashi-ku, Tokyo , Japan
192 Journal of Health Science, 47(2) 192 22 (21) Investigation of the Effects of Tamsulosin on Blood Pressure in Normotensive, Controlled Hypertensive, and Uncontrolled Hypertensive Men with Benign Prostatic
More informationRole of silodosin in patients with LUTS/BPE non responding to medical treatment with tamsulosin: a prospective, open-label, pilot study
European Review for Medical and Pharmacological Sciences 2017; 21: 4941-4945 Role of silodosin in patients with LUTS/BPE non responding to medical treatment with tamsulosin: a prospective, open-label,
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FLOMAX safely and effectively. See full prescribing information for FLOMAX. FLOMAX (tamsulosin hydrochloride,
More informationOVER 70% OF MEN IN THEIR 60s HAVE SYMPTOMS OF BPH 1
PATIENT INFORMATION BPH affects more than 500 million men worldwide, with many men suffering from symptoms of enlarged prostate. 1 You no longer have to be one of them! OVER 70% OF MEN IN THEIR 60s HAVE
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) Date of FAR:
Core Safety Profile Active substance: Doxazosin Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) P - RMS: DK/H/PSUR/0004/002 Date of FAR: 12.12.2011 4.3 Contraindications
More informationEffects of Tamsulosin on Premature Ejaculation in Men with Benign Prostatic Hyperplasia
pissn: 2287-4208 / eissn: 2287-4690 World J Mens Health 2014 August 32(2): 99-104 http://dx.doi.org/10.5534/wjmh.2014.32.2.99 Original Article Effects of Tamsulosin on Premature Ejaculation in Men with
More informationWill Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men?
Urol Sci 2011;22(1):14 18 MINI REVIEW Will Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men? Thomas I.S. Hwang 1,2,3 * 1 Shin Kong WHS Hospital, Taipei,
More informationComparison of Silodosin versus Tadalafil in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia
LUTS (2017) 9, 176 186 ORIGINAL ARTICLE Comparison of Silodosin versus Tadalafil in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia Masaki YOSHIDA, 1, Hideki ORIGASA,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Alfuzosin Stada 5 mg prolonged-release tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg alfuzosin hydrochloride.
More informationEfficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study
Efficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study Yoshihisa Matsukawa,* Momokazu Gotoh, Tomonori Komatsu, Yasuhito Funahashi, Naoto Sassa and Ryohei Hattori
More informationAbstract. Key words Trial without catheter, Acute urinary retention, Benign prostatic hyperplasia, Introduction
The role of sustained-released alfuzosin in the treatment of acute urinary retention Mohamed Fawzi Ahmed. Department of Surgery, Ninevah College of Medicine, University of Mosul. Abstract To see whether
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Tamsuda 0,4 mg, tabletten met verlengde afgifte 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each prolonged-release tablet contains 0.400
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationOffice Management of Benign Prostatic Enlargement
Focus on CME at McGill University Office Management of Benign Prostatic Enlargement Symptomatic benign prostate enlargement is a common medical problem encountered in our aging society. Watchful waiting,
More informationPRODUCT MONOGRAPH. (tamsulosin hydrochloride) Controlled-Release Tablets 0.4 mg
PRODUCT MONOGRAPH Pr TAMSULOSIN CR (tamsulosin hydrochloride) Controlled-Release Tablets 0.4 mg SELECTIVE ANTAGONIST OF ALPHA 1A / 1D ADRENORECEPTOR SUBTYPES IN THE PROSTATE AND BLADDER SANIS HEALTH INC.
More informationImpact of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Treatment with Tamsulosin and Solifenacin Combination Therapy on Erectile Function
www.kjurology.org DOI:10.4111/kju.2011.52.1.49 Sexual Dysfunction Impact of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Treatment with Tamsulosin and Solifenacin Combination Therapy on Erectile
More informationSingle Technology Appraisal (STA) Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia
Comment 1: the draft remit Appendix D - NICE s response to consultee and commentator comments on the draft scope and provisional matrix National Institute for Health and Clinical Excellence Single Technology
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Prolonged release tablets, 4 mg and 8 mg (GITS) Date of FAR:
Core Safety Profile Active substance: Doxazosin Pharmaceutical form(s)/strength: Prolonged release tablets, 4 mg and 8 mg (GITS) P - RMS: DK/H/PSUR/0004/002 Date of FAR: 12.12.2011 4.3 Contraindications
More informationChapter 4: Research and Future Directions
Chapter 4: Research and Future Directions Introduction Many of the future research needs listed in the 1994 Agency for Health Care Policy and Research (AHCPR) clinical practice guideline Benign Prostatic
More informationMedical Therapy for Benign Prostatic Hyperplasia Present and Future Impact
REPORTS Medical Therapy for Benign Prostatic Hyperplasia Present and Future Impact Muta M. Issa, MD, MBA; Timothy S. Regan, BPharm, RPh, CPh Abstract The purpose of this manuscript is to provide clinicians,
More informationThe treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years
British Journal of Urology (1997), 8, 875 879 The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 8 years S.A. KAPLAN, A.E. TE, E. IKEGUCHI and R.P. SANTAROSA Department
More informationFerdinando Fusco * , Massimiliano Creta, Nicola Longo, Francesco Persico, Marco Franco and Vincenzo Mirone
Fusco et al. BMC Urology (2018) 18:12 https://doi.org/10.1186/s12894-018-0326-7 RESEARCH ARTICLE Open Access Silodosin 8 mg improves benign prostatic obstruction in Caucasian patients with lower urinary
More informationUroToday International Journal. Volume 1 - August 2008
UroToday International Journal www.urotodayinternationaljournal.com Volume 1 - August 2008 Complicated Cataract Surgery in Patients Receiving Alpha-Blockers for Benign Prostatic Hyperplasia Ryan K. Miyamoto*,
More informationLast Review Status/Date: December Summary
Section: Surgery Effective Date: January 15, 2016 Subject: Prostatic Urethral Lift Page: 1 of 9 Last Review Status/Date: December 2015 Summary Benign prostatic hyperplasia (BPH) is a common condition in
More informationPRABHAKAR SINGH*, MANOJ INDURKAR, AMITA SINGH, PALLAVI INDURKAR
Academic Sciences International Journal of Current Pharmaceutical Research ISSN- 0975-7066 Vol 5, Issue 1, 2013 Research Article COMPARISON OF THE EFFICACY AND SAFETY OF TAMSULOSIN (0.4 V/S (and) FINASTERIDE
More informationPRODUCT MONOGRAPH SANDOZ ALFUZOSIN
PRODUCT MONOGRAPH Pr SANDOZ ALFUZOSIN Alfuzosin Hydrochloride Prolonged-Release Tablets 10 mg Pharmaceutical standard: Professed Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH) Adjunctive Therapy
More informationThe Journal of International Medical Research 2005; 33:
The Journal of International Medical Research 2005; 33: 562 573 A Comparative Study on the Safety and Efficacy of Tamsulosin and Alfuzosin in the Management of Symptomatic Benign Prostatic Hyperplasia:
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION. Pr XATRAL. Alfuzosin Hydrochloride Prolonged-Release Tablets 10 mg
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr XATRAL Alfuzosin Hydrochloride Prolonged-Release Tablets 10 mg Pharmaceutical standard: Professed Symptomatic Treatment of Benign Prostatic
More informationOriginal Research Article
International Surgery Journal Singh SN et al. Int Surg J. 218 May;():1866-1872 http://www.ijsurgery.com pissn 2349-33 eissn 2349-292 Original Research Article DOI: http://dx.doi.org/1.1823/2349-292.isj218199
More informationCurrent drug management of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol
Drug review BPH Current drug management of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol Skyline Imaging Ltd The range of drug treatments for BPH, alone
More informationfor ED and LUTS/BPH Pierre Sarkis, M.D. Assistant Professor Fellow of the European Board of Urology
Tadalafil 5 mg once daily for ED and LUTS/BPH Pierre Sarkis, M.D. Assistant Professor Fellow of the European Board of Urology Why this conference? Not promotional but educational The pharmacist regularly
More informationBenign Prostatic Hyperplasia (BPH) Important Papers / Landmark. Vijayan Manogran
Benign Prostatic Hyperplasia (BPH) Important Papers / Landmark Studies Vijayan Manogran MTOPS & CombAT PLESS SMART ALTESS ALF-ONE VA PREDICT EPICS Landmark Studies MTOPS Medical Therapy of Prostatic Symptoms
More informationXATRAL XL 10 mg prolonged release tablets
1. NAME OF THE MEDICINAL PRODUCT XATRAL XL 10 mg prolonged release tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Alfuzosin hydrochloride 10 mg for one prolonged release tablet For excipients, see
More informationMANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH
MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH INTRODUCTION (1) Part of male sexual reproductive organ Size
More informationeuropean urology 53 (2008)
european urology 53 (2008) 1236 1244 available at www.sciencedirect.com journal homepage: www.europeanurology.com Benign Prostatic Enlargement A Randomised, Placebo-Controlled Study to Assess the Efficacy
More informationa 1 -adrenoceptor antagonist on uro owmetric parameters in patients with benign prostatic hyperplasia
Single dose methodology to assess the in uence of an a 1 -adrenoceptor antagonist on uro owmetric parameters in patients with benign prostatic hyperplasia S. P. Curtis, 1 I. Eardley, 2 M. Boyce, 3 P. Larson,
More informationCombination Drug Therapy for Benign Prostatic Hyperplasia (BPH)
The Annals of African Surgery www.sskenya.org Combination Drug Therapy for Benign Prostatic Hyperplasia (BPH) Author: Oliech J.S. FRCS, Affiliation: Department of Surgery, University of Nairobi. P.O. Box
More informationCialis. Cialis (tadalafil) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.06.02 Subject: Cialis Page: 1 of 5 Last Review Date: September 18, 2015 Cialis Description Cialis (tadalafil)
More informationRELATIONSHIPS BETWEEN AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX, PROSTATE VOLUME, PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
American Urological Association symptom index for BPH RELATIONSHIPS BETWEEN AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX, PROSTATE VOLUME, AND DISEASE-SPECIFIC QUALITY OF LIFE QUESTION IN PATIENTS WITH
More informationPRODUCT MONOGRAPH. AURO-ALFUZOSIN Alfuzosin Hydrochloride Prolonged-Release Tablets 10 mg. House Standard
PRODUCT MONOGRAPH Pr AURO-ALFUZOSIN Alfuzosin Hydrochloride Prolonged-Release Tablets 10 mg House Standard Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH) Adjunctive Therapy in Acute Urinary
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTISTICS 1 NAME OF THE MEDICINAL PRODUCT Xatral XL 10 mg prolonged release tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10mg alfuzosin hydrochloride.
More informationProstate Disease. Chad Baxter, MD
Prostate Disease Chad Baxter, MD Managing BPH and LUTS Chad Baxter, MD Department of Urology cbaxter@mednet.ucla.edu 33 nd Annual UCLA Intensive Course in Geriatric Medicine & Board Review Prevalence of
More information